This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G31.81 | Special Copayment Reduction: V208 | Coverage period: 5 years |
| B. Synonyms | Leigh syndrome, Leigh disease, subacute necrotizing encephalopathy, subacute necrotizing encephalomyelopathy, Leigh's encephalopathy, SNE (Subacute Necrotizing Encephalomyelopathy) |
| C. Adult onset | Likelihood of first onset in adulthood very low — most cases begin in infancy to childhood (3~12 months of age); an adult form (adult-onset Leigh syndrome) rarely exists and is mainly associated with mtDNA variants of the MTATP6 and MT-ND families |
| 1. History | 1. History |
| 2. Causes | 2. Causes |
| 3. Genetics | 3. Genetics |
| 4. Epidemiology | 4. General epidemiology |
| 5. Pathophysiology | 5. Pathophysiology |
| 6. Symptoms | 6. Symptoms |
| 7. Signs | 7. Signs |
| 8. Screening | 8. Screening |
| 9. Diagnosis | 9. Diagnosis |
| 10. Treatment | 10. Treatment |
| 11. Prognosis | 11. Prognosis |
| 12. Prevention | 12. Prevention |
| 13. References | 13. References |
Leigh disease/syndrome is a rare neurodegenerative disease first described in 1951 by the British neuropathologist Denis Leigh (1915–1998) in the Journal of Neurology, Neurosurgery & Psychiatry. At autopsy of a boy who became ill at 7 months of age and died 6 weeks later, Leigh identified characteristic bilateral symmetric spongiform necrosis and vascular proliferation involving the brainstem and basal ganglia, and named this "subacute necrotizing encephalomyelopathy."
In 1968, Worsley et al. reported the presence of a urinary factor that inhibits the synthesis of thiamine triphosphate, and an abnormality of thiamine metabolism temporarily drew attention as the cause, but this was not supported by subsequent studies. In the 1970s–80s, cytochrome c oxidase (Complex IV; COX) deficiency was identified in some patients with Leigh disease, and as mitochondrial DNA (mtDNA) variant analysis techniques were introduced into clinical practice from the late 1980s, mtDNA variants were found to be one of the causes of this disease.
After the SURF1 gene was identified as a COX assembly factor in 1993, in 1998 Tiranti et al. and Zhu et al. each independently reported that SURF1 gene mutations are a major cause of COX-deficient Leigh disease. Subsequently, with the spread of next-generation sequencing (NGS), variants in more than 100 related genes in nuclear DNA (nDNA) and mtDNA have been identified, and the view that Leigh disease is not a single disease but a clinically and genetically highly heterogeneous syndrome spectrum (Leigh syndrome spectrum, LSS) is now established.
The fundamental cause of Leigh disease is dysfunction of mitochondrial oxidative phosphorylation (OXPHOS); because intracellular ATP production is insufficient, brainstem and basal ganglia neurons with high energy demands are selectively damaged. The specific biochemical causes are classified as follows.
Pyruvate dehydrogenase complex (PDHC) deficiency shows neuropathological and clinical phenotypes similar to Leigh disease. Variants in PDHA1 (X-linked), PDHB, and DLAT have been reported. CoQ10 deficiency due to variants in coenzyme Q10 (CoQ10) biosynthesis genes (COQ2, COQ4, COQ8A/B, etc.) also causes a Leigh-like phenotype.
POLG (mitochondrial DNA polymerase gamma) variants cause mtDNA depletion or multiple deletions, resulting in Leigh-like or Leigh-plus syndrome. TWNK (helicase Twinkle), DGUOK, and MPV17 variants are also involved.
Leigh disease is a genetically highly heterogeneous disease, and variants in more than 100 genes have been reported to date. The mode of inheritance differs depending on the gene.
| Mode of inheritance | Related genes (examples) | Proportion (literature) |
|---|---|---|
| Autosomal recessive (AR) | SURF1, SDHA, NDUFS4, NDUFS7, NDUFS8, SCO2, COX10, COX15, POLG | About 54% |
| Maternal inheritance (mtDNA) | MTATP6, MT-ND1~6, MT-ND4L, MT-TL1, MT-TV | About 35% |
| X-linked recessive | PDHA1, NDUFA1 | <5% |
| Autosomal dominant | Some heterozygous POLG variants, SDHA | Rare |
SURF1 (Surfeit locus protein 1, 9q34): as a COX assembly factor, SURF1 variants are the most common single cause of COX-deficient Leigh disease. They mainly present with a non-sensorineural phenotype, and in some patients hypertrichosis is a clinical clue. In an Italian cohort study, SURF1 variants accounted for about 28% of all Leigh disease.
MTATP6 (m.8993T>G/C): the heteroplasmy level is directly linked to prognosis. A mutation load >90% tends to produce the Leigh disease phenotype, and 70–90% the NARP phenotype.
NDUFS4: a Complex I subunit variant; the NDUFS4-deficient mouse model (Ndufs4 KO mouse) has been used as a representative animal model of Leigh disease and has contributed to treatment research such as rapamycin.
Key points of genetic counseling: for mtDNA variants, standard Mendelian inheritance does not apply, making genetic counseling complex. The heteroplasmy level can differ between tissues and between generations (mitotic segregation), and asymptomatic maternal relatives carrying a pathogenic mtDNA variant may exist. For AR genetic diseases, parental carrier testing and prenatal diagnosis (chorionic villus sampling or amniocentesis) are possible.
Leigh disease is a rare disease estimated at 1 per 36,000~40,000 live births (birth prevalence about 1:36,000–40,000) and is the most common single phenotype among pediatric mitochondrial diseases. Sex differences vary with the mode of inheritance, but overall there is no clear sex difference (except for X-linked PDHA1 variants).
The median age of onset is about 3 months of age, and about 79% of all patients develop symptoms within the first year of life. In a large cohort (n=120) of the Italian mitochondrial disease network (IMNPD), the age of onset ranged from in utero to 6.6 years. Adult-onset Leigh disease (adult-onset LS) is reported in less than 10% of all cases and is mainly associated with mtDNA MTATP6 variants (especially m.9176T>C), MT-ND variants, or POLG variants.
Founder effects in specific ethnic groups and regions have been reported. The incidence of COX-deficient Leigh disease due to LRPPRC variants is high in the French-Canadian population of Quebec, Canada; SDHA variants are observed in the Palestinian Arab population, and a phenotype overlapping with GRACILE syndrome (BCS1L variants) in the Finnish population. Cases of Leigh disease due to SURF1 variants and mtDNA variants have also been reported in East Asian populations, including Korea.
Accurate domestic prevalence data have not yet been systematically compiled, but registration status is gradually being established through Health Insurance Review & Assessment Service (HIRA) Special Copayment Reduction registration data (code V208).
The core pathophysiology of Leigh disease is reduced ATP production, overproduction of reactive oxygen species (ROS), and lactic acidosis due to dysfunction of the mitochondrial oxidative phosphorylation (OXPHOS) enzyme complexes. The brain accounts for only about 2% of body weight but about 20% of total body oxygen consumption; in particular, the reticular activating system of the brainstem, the basal ganglia (especially the putamen and caudate nucleus), and the thalamus are highly energy-dependent and therefore most vulnerable to OXPHOS impairment.
Gross and microscopic findings are characterized by spongiform degeneration, capillary proliferation, reactive astrogliosis, and neuronal loss distributed bilaterally and symmetrically in the basal ganglia (putamen > caudate nucleus > globus pallidus), thalamus, brainstem (periaqueductal region, pons, medulla), and cerebellar dentate nucleus. Myelin tends to be relatively preserved, which distinguishes it from primary demyelinating diseases.
The clinical presentation varies with age of onset, the causative gene variant, and the brain structures involved. In most patients, feeding difficulties, failure to thrive, and recurrent vomiting appear as early symptoms.
The objective signs identified on physical examination are as follows.
MRI: symmetric T2/FLAIR hyperintense lesions of the bilateral basal ganglia (putamen) and brainstem are most characteristic. Lesions may be hypointense or isointense on T1 and may show restricted diffusion on diffusion-weighted imaging (DWI) in the acute phase. On magnetic resonance spectroscopy (MRS), decreased N-acetylaspartate (NAA) and an elevated lactate doublet (doublet at 1.33 ppm) are findings suggestive of mitochondrial disease.
Leigh disease is not included in newborn screening (NBS), but primary clinical screening for early diagnosis proceeds in the following steps.
In infants and children with developmental regression or neurological abnormalities, brain MRI (including T2/FLAIR) is performed early to check for bilateral basal ganglia and brainstem T2 hyperintense lesions. CT is not recommended as the first-line imaging test because of concerns about radiation exposure and low sensitivity for detecting early lesions.
When Leigh disease or mitochondrial disease has been confirmed in a sibling or parent, metabolic monitoring (blood and urine lactate, serum lactate/pyruvate ratio) and neurodevelopmental follow-up should be performed from the neonatal period. For mtDNA variants (especially m.8993T>G/C), molecular genetic fetal diagnosis is possible.
Confirmation is made by integrating clinical, neuroimaging, biochemical, and genetic test findings. In many cases a single test alone cannot confirm the diagnosis, and a multidisciplinary approach (neurology, metabolic medicine, medical genetics, neuroradiology) is essential.
On muscle biopsy (fresh frozen tissue), respiratory chain complex enzyme activities (Complex I~V, PDH) are measured. Succinate COX (sCOX) histochemical staining is useful for visualizing COX-negative muscle fibers.
Currently, a next-generation sequencing (NGS)-based mitochondrial disease panel or whole-exome sequencing (WES) is recommended as the first-line molecular diagnostic method. mtDNA analysis (whole mtDNA sequencing, deletion analysis) should be performed together with a nuclear gene panel, and the diagnostic yield is 50–75% depending on the cohort. Even without molecular genetic confirmation, clinical Leigh disease can be diagnosed if the clinical, imaging, and biochemical findings are consistent.
To date there is no established curative treatment for Leigh disease, and treatment is based on a symptomatic and supportive approach.
Ketogenic diet (KD): in Complex I deficiency and PDHC deficiency, ketone bodies enter the TCA cycle directly and generate ATP, reducing dependence on glucose. KD is currently the best-evidenced non-pharmacological treatment for Leigh disease, and some studies have reported reduced seizures, stabilized neurodevelopment, and prolonged survival. An MCT diet is also used as an alternative. However, evidence of efficacy is insufficient for MTATP6 variants (Complex V deficiency).
Rapamycin (an mTORC1 inhibitor) was shown to markedly prolong survival in Ndufs4-deficient mice (Johnson SC et al., Science, 2013). N-acetylcysteine (NAC) is administered experimentally in some patients on the basis of reducing ROS through its antioxidant effect. Gene therapy (AAV-based), mitochondria-targeted antioxidants (MitoQ), and mRNA therapy are being studied at the preclinical stage. In an AAV gene therapy study in NDUFS4-deficient mice (Reynaud-Dulaurier et al., Brain, 2020), improvement of brain lesions was reported, showing potential for clinical translation.
The overall prognosis of Leigh disease is poor and varies by causative gene and age of onset. In the COX-deficient type due to SURF1 variants, most patients die before age 10. In an Italian cohort study, the median survival was about 7 years. The main causes of death are respiratory failure and pneumonia.
Among patients carrying the MTATP6 m.8993T>G variant, those with low heteroplasmy levels may show a relatively favorable course, and some adult-onset cases have been reported to survive for decades with a mild phenotype. Leigh disease due to CoQ10 deficiency may show a relatively favorable prognosis with high-dose CoQ10 supplementation.
Acute exacerbation episodes (intercurrent infection, fever, metabolic stress) can cause abrupt decline of neurological function, so prevention and early management are important. In some patients, a "flickering" pattern is observed in which brain MRI lesions repeatedly improve and worsen. The adult-onset form tends to progress more slowly and have longer survival than the pediatric-onset form.
There is currently no way to prevent Leigh disease itself, but assisted reproductive technologies are used to prevent recurrence in families at genetic risk.
For AR genetic diseases (nuclear gene variants such as SURF1 and NDUFS4), the recurrence risk for heterozygous carrier parents is 25% (per pregnancy). Recurrence can be prevented by selecting and transferring unaffected embryos through preimplantation genetic testing (PGT-M, preimplantation genetic testing for monogenic disorders). Prenatal molecular genetic diagnosis by chorionic villus sampling (10–13 weeks) or amniocentesis (15–18 weeks) is also possible.
For Leigh disease due to mtDNA variants, mitochondrial replacement therapy (MRT) based on pronuclear transfer or spindle transfer has been licensed for clinical use, mainly in the United Kingdom. Transmission of pathogenic mtDNA is prevented by transferring the maternal nucleus into an enucleated donor egg containing almost no mtDNA mutations. However, heteroplasmy reversion after MRT—that is, a renewed increase in the proportion of maternal mtDNA—has been reported in some cases, so further observation of long-term effects is needed.
Infection, fever, general anesthesia, excessive exercise, and the like can trigger acute exacerbations of Leigh disease. Vaccinations should be thoroughly administered, fever should be actively treated with antipyretics, and when general anesthesia is required, prior consultation with a specialist should ensure selection of anesthetics with low mitochondrial toxicity (avoiding prolonged propofol administration, caution with inhaled anesthetics).